TDM Instructions & Submission Guidelines Authorization to Import Research & Diagnostic Samples FREE Therapeutic Drug Monitoring (TDM) and AGP assays What […]
FREE Therapeutic Drug Monitoring (TDM) and AGP assays Read More »
TDM Instructions & Submission Guidelines Authorization to Import Research & Diagnostic Samples FREE Therapeutic Drug Monitoring (TDM) and AGP assays What […]
FREE Therapeutic Drug Monitoring (TDM) and AGP assays Read More »
Péritonite Infectieuse Féline – Protocoles Actuels et Présentation de Cas Cliniques Nous avons le plaisir de partager un webinaire offert
Péritonite Infectieuse Féline – Protocoles Actuels et Présentation de Cas Cliniques Read More »
This episode brings together Dr. Sally Coggins (University of Sydney), Prof. Danielle Gunn-Moore, and Dr. Sam Taylor for a 2025
GS-441524 in the Treatment of Feline Infectious Peritonitis: When to Choose Oral or Injectable Forms Feline infectious peritonitis (FIP) is a
GS-441524 for FIP: When to Choose Oral or Injectable Read More »
In this episode, Dr. Sam Taylor, Dr. Sally Coggins and Prof. Danielle Gunn-Moore cover: How diagnostic thinking for FIP
FIP Confusers And Unusual Presentations, with a Focus on the UK Cat Population: Read More »
Paving the Way for Regulated FIP Treatment in Canada – 2022: Case Series Study Combining GS-441524 and Mefloquine In 2022,
Paving The Way for Regulated FIP Treatment Read More »
FIP Road Signs & Red Flags In this episode, Dr. Sam Taylor and Prof. Danielle Gunn-Moore cover: Signalment clues for
FIP Road Signs & Red Flags Read More »
The Long and Winding Road to Finding a Cure for FIP – A Brief History of GS For decades, Feline
A Brief History of GS Read More »
GS-441524 testimonial as per Dr. Mathew Best “Feline infectious peritonitis (FIP) has historically been a 100% fatal disease with no
FIP Testimonial – Ontario Read More »
Molnupiravir for the Treatment of Feline Infectious Peritonitis (FIP): Mechanism, Evidence, and Clinical Application In this session, veterinarians will: Review
Molnupiravir Webinar Read More »